Abbisko Cayman (HKG:2256) said its subsidiary, Abbisko Therapeutics, has dosed the first patient in a Phase 1 clinical trial of ABSK131, a novel PRMT5*MTA inhibitor targeting advanced or metastatic solid tumors with MTAP deficiency, according to a Wednesday Hong Kong bourse filing.
Shares of the company gained as much as 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.